143 In the index

Leuprolide LEUP

An FDA-approved hormone-blocking medication used for prostate cancer, endometriosis, early puberty, and gender-affirming care. Extensive research supports all these uses, and the hormone-suppression side effects are an expected, well-understood part of how it works.

Also known as Lupron

Effects Hormonal

Routes Injectable Subcutaneous

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₅₉H₈₄N₁₆O₁₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C59H84N16O12
Molar mass: 1209.4
CAS: 53714-56-0
PubChem CID: 657181

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 3.75-22.5 mg depending on formulation and interval

Reported range Varies widely by depot formulation (monthly, 3-month, 4-month, 6-month) and indication

Route Intramuscular or subcutaneous injection

Frequency Monthly to every 6 months, depending on depot formulation

Duration Chronic/ongoing (as prescribed)

FDA-approved GnRH agonist (Lupron) for prostate cancer, endometriosis, and precocious puberty; dosing is highly formulation-specific and physician-directed.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.

Variants

Name	Abbr	Route	Notes
Leuprolide depot	LEUP-D	Injectable	Long-acting depot injection lasting one to six months.